Biomedical subjects

Brian A Vesely

Publications and source records attributed to Brian A Vesely.

3 recordsLinked to original sources

PubMed2006

Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells.

BACKGROUND: A family of six cardiovascular hormones--atrial natriuretic peptide, brain natriuretic peptide, C-natriuretic peptide, long acting natriuretic peptide, vessel dilator and kaliuretic peptide--was investigated for the ability to decrease the number of human angiosarcoma cells. METHODS AND RESULTS: Within 24 h, vessel dilator, long acting natriuretic peptide, kaliuretic peptide, atrial natriuretic peptide and their intracellular mediator cyclic GMP decreased the number of angiosarcoma cells by 61, 30, 29, 36 and 32%, respectively, and DNA synthesis by 68-85%. Brain natriuretic peptide and C-natriuretic peptide had no effect(s). The natriuretic peptide receptor C was present. CONCLUSIONS: Four cardiovascular hormones decrease the number of angiosarcoma cells within 24 h via inhibition of DNA synthesis mediated in part by cyclic GMP.

Analysis of Variance↗

PubMed2006

Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells.

Within 24 h four peptide hormones, i.e. vessel dilator, long acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide and their intracellular mediator cyclic GMP decreased the number of human squamous lung cancer cells 51, 22, 25, 21, and 30%, respectively. There was not any proliferation in the 3 days following this decrease in cell number. Vessel dilator decreased DNA synthesis 85% in the squamous lung cancer cells. Thus, vessel dilator significantly decreased the number of human squamous lung cancer cells and their DNA synthesis, mediated in part by cyclic GMP, more than other peptide hormones.

Atrial Natriuretic Factor↗

PubMed2005

Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via cyclic GMP.

BACKGROUND: Mortality from colon cancer is significant with an expected 30,350 colon cancer deaths in 2005 with current treatment(s). Long-acting natriuretic peptide, vessel dilator, kaliuretic peptide, and atrial natriuretic peptide have significant anticancer effects in breast and pancreatic adenocarcinomas. AIM OF STUDY: Whether these peptide hormones have anticancer effects in colon adenocarcinoma cells and whether these effects are specifically mediated by cyclic GMP has not been determined. METHODS: These peptide hormones were evaluated for anticancer effects in human colon adenocarcinoma cells and to determine whether their anticancer effects are specifically mediated by cyclic GMP. RESULTS: There was a 89-97% decrease (p <0.001 for each) in colon adenocarcinoma cells within 24 h with 1 mM of these peptide hormones. There was a significant (p <0.05) decrease in human colon cancer cell number with each 10-fold increase in concentration from 1 to 1,000 microM (i.e., 1 mM) of these four peptide hormones without any proliferation in the 3 d following this decrease. These same hormones decreased DNA synthesis 65-83% (p <0.001). Cyclic GMP antibody inhibited 75- 80% of these peptides' ability to decrease colon adenocarcinoma cell number and inhibited 92-96% of their DNA synthesis effects and 97% of cyclic GMP's effects. Western blots revealed that for the first time natriuretic peptide receptors (NPR) A and C were present in colon adenocarcinoma cells. CONCLUSIONS: Four peptide hormones eliminate up to 97% of colon cancer cells within 24 h with their DNA effects specifically mediated by cyclic GMP.

Adenocarcinoma↗